|
 DOWNLOAD
INTERVIEW HERE
This
interview requires the Windows Media Player
Interview
conducted by: STOCKHOUSE.COM
Topics
covered in the Interview:
Samaritan
is a small cap biopharmaceutical company focused on the development
of novel therapeutic and diagnostic products. We have devoted
substantially all of our resources to undertaking drug discovery
and development programs.
The majority
of our resources have been expended in the pursuit of Food
and Drug Administration (FDA) required preclinical
studies and Phase II/III clinical trials for Samaritan's
HIV drug, SP-01A (Sphirewall), an oral entry inhibitor.
In a previous Phase I/II study, SP-01A
was observed to significantly lower the amount of HIV in the
blood, improve quality of life (how well subjects have felt),
have a favorable safety profile (minimal side effects) and
be well-tolerated. Moreover, in vitro testing of SP-01A:
(a) demonstrated comparable or greater efficacy than currently
approved anti-HIV drugs in preventing HIV virus replication;
(b) was observed to have minimal toxic effect on human cells;
and (c) demonstrated significant efficacy in preventing virus
replication of HIV virus strains resisting currently approved
anti-HIV treatments. The goal of our SP-01A
monotherapy study is to look further at the dose response,
efficacy and safety of SP-01A
as monotherapy, given as a capsule to be swallowed, in the
treatment of HIV-infected subjects. We are no longer recruiting
patients for this study but are in the process of completing
the trial.
In addition,
and at the same time, Samaritan has devoted major resources
to its Alzheimer's
technology, which features: (a) three (3) therapeutics:
SP-04, SP-08 and SP-233;
(b) two (2)
stem cell, neuron differentiation therapies: SP-sc4 and SP-sc7;
(c) a
predictive Alzheimer's diagnostic; and (d) an
Alzheimer's animal model. Samaritan has also devoted resources
to its cancer drug, SP-C007, a
breast cancer diagnostic and its cholesterol
recognition peptide, which plays a role in transforming and
binding LDL cholesterol while subsequently raising HDL.
Samaritan
has established its European headquarters in Athens, Greece,
which we believe will allow access to the markets of Eastern
Europe, Asia and Africa, regions with a high proportion of
HIV patients and a target population for our most advanced
drug, SP-01A. Samaritan
Pharmaceuticals Europe ("Samaritan") is currently
seeking to build a sales and marketing infrastructure through
distribution agreements for niche, high valued products from
other companies in the fields of HIV/infectious diseases,
CNS, cancer/oncology and cardiovascular diseases for the normally
undeveloped regions of Greece, Turkey, Bulgaria, Romania,
Croatia, Serbia, Bosnia and Slovenia.
About Samaritan
Pharmaceuticals: ``We LIV....to Save Lives.''
Samaritan is a
small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics' for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
Samaritan Pharmaceuticals
-- Samaritan Technology Videos: http://www.samaritanpharma.com/samaritan_mechanism_of_action_videos.asp
The company
disclaims any information that is created by an outside party
and endorses only information that is communicated by its
press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current
beliefs about the potential for its drug candidates, science
and technology. However, as with any biopharmaceutical under
development, there are significant risks and uncertainties
in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. For additional information about the factors that
affect the company's business, please read the company's latest
Form 10-K/A filed November 2, 2006. The company undertakes
no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
